UCM707

UCM707 is a potent and selective inhibitor of the endocannabinoid transporter, particularly inhibiting the uptake of anandamide, an endogenous cannabinoid. Its IC50 for inhibition of the anandamide transporter is 0.8 μM, and for FAAH (fatty acid amide hydrolase) is 30 μM. UCM707 effectively potentiates hypokinetic and antinociceptive effects of anandamide, showing minimal direct action on cannabinoid receptors (CB1, CB2, VR1), but significantly potentiating the action of endogenous cannabinoids. This profile makes it a promising research tool or possible therapeutic agent for disorders like pain, Huntington's disease, multiple sclerosis, and diabetic neuropathy, especially through symptom alleviation, but with no confirmed neuroprotective effect[1][2][3][5][7].

Other names

N-(3-furylmethyl)eicosa-5,8,11,14-tetraenamide